Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of AK127 combined with AK112 in advanced solid tumors
CTR20231654Phase 2Active
- Sponsor
- Akeso, Inc.
- Start
- Aug 2023
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of AK127, ivonescimab in Nonhematologic neoplasms, sponsored by Akeso, Inc.. Started Aug 2023; status: active.
02
Drugs
AK127ivonescimab
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20231654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231654.